Fortgeschrittene systemische Mastozytose Hintergrundinformationen zu einer seltenen Erkrankung und zur ersten zugelassenen Therapie
|
|
- Joy Pierce
- 6 years ago
- Views:
Transcription
1 Fortgeschrittene systemische Mastozytose Hintergrundinformationen zu einer seltenen Erkrankung und zur ersten zugelassenen Therapie Georgia Metzgeroth Hämatologie und Onkologie III. Medizinische Klinik Universitätsklinikum Mannheim
2 Common features in systemic mastocytosis: KIT D816V, dense mast cell infiltrates and serum tryptase KIT D816V Tryptase BM and PB Serum BM: Bone Marrow; PB: Peripheral Blood Mast cell infiltrate
3 Systemic mastocytosis Organ infiltration Bone marrow Liver Advanced SM * SM-AHN, ASM, MCL BM MC infiltration Serum tryptase Spleen Lymph nodes GI tract Skin Indolent SM 80-90% KIT D816V 60-70% KIT D816V Allele burden allele burden Organ damage = C-findings Cytopenia(s) associated hematologic neoplasm (AHN) MDS/MPN MDS MPN saml Monocytosis Eosinophilia Dysplasia Blasts Elevated liver enzymes (AP!) Portal hypertension Splenomegaly Ascites Hypoalbuminemia Malabsorption Osteolyses * Advanced SM: SM with associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), mast cell leukemia (MCL) MDS: Myelodysplastic Syndrome, MPN: Myeloproliferative Neoplasm, saml: secondary Acute Myeloid Leukemia; AP: Alkaline Phosphatase; BM: Bone Marrow
4 WHO diagnostic criteria of systemic mastocytosis (SM) Major Multifocal compact mast cell infiltrates (>15 MC) in bone marrow or other extracutaneous organs Minor Mast cell with atypical morphology (>25% MC) KIT D816V mutation Aberrant expression of CD2 and/or CD25 Serum tryptase >20 ng/ml (normal <11.4) SM: major + 1 minor or 3 minor criteria
5 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS etc.
6 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS etc.
7 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS. Suspected systemic mastocytosis (SM) BONE MARROW (BM) BIOPSY Aspirate, histology, immunohistochemistry, cytogenetics, FACS analysis Quantification of mast cell (MC) infiltration Presence and quantification of KIT D816V 2 Mast cell leukemia (MCL)? 3 Associated hematologic neoplasm (AHN)? Multilineage involvement? CD34+ blasts? Diagnosis of SM (according to WHO 2016): 1 major + 1 minor criterion or >3 minor criteria Major criterion Multifocal dense infiltrates of MCs, 15 MCs in aggregates in BM biopsies Minor criteria (modified) 25% of all MCs are atypical cells (type I or type II) on BM smears or are spindleshaped in MC infiltrates detected on sections of visceral organs KIT D816 mutation or other activating KIT mutation MCs exhibit CD25 (and/or CD2) Baseline serum tryptase level >20 µg/l
8 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS. Suspected systemic mastocytosis (SM) BONE MARROW (BM) BIOPSY Aspirate, histology, immunohistochemistry, cytogenetics, FACS analysis Quantification of mast cell (MC) infiltration Presence and quantification of KIT D816V 2 Mast cell leukemia (MCL)? 3 Associated hematologic neoplasm (AHN)? Multilineage involvement? CD34+ blasts? Diagnosis of SM (according to WHO 2016): 1 major + 1 minor criterion or >3 minor criteria B- or C-findings? Major criterion Multifocal dense infiltrates of MCs, 15 MCs in aggregates in BM biopsies Minor criteria (modified) 25% of all MCs are atypical cells (type I or type II) on BM smears or are spindleshaped in MC infiltrates detected on sections of visceral organs KIT D816 mutation or other activating KIT mutation MCs exhibit CD25 (and/or CD2) Baseline serum tryptase level >20 µg/l B-findings BM MC infiltration >30% and serum tryptase >200µg/L Organomegaly BM with proliferation or dysplasia C-findings Cytopenia(s): Neutrophils <1x10 9 /μl, Hb<10 g/dl and/or platelets <100x10 9 /μl Hepatomegaly with impaired liver function and ascites Palpable splenomegaly + associated hypersplenism Malabsorption with hypoalbuminemia and significant weight loss Skeletal lesions: large-sized osteolyses with pathologic fractures Life-threatening organ damage in other organ systems that is caused by local MC infiltration
9 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS. Suspected systemic mastocytosis (SM) BONE MARROW (BM) BIOPSY Aspirate, histology, immunohistochemistry, cytogenetics, FACS analysis Quantification of mast cell (MC) infiltration Presence and quantification of KIT D816V 2 Mast cell leukemia (MCL)? 3 Associated hematologic neoplasm (AHN)? Multilineage involvement? CD34+ blasts? Diagnosis of SM (according to WHO 2016): 1 major + 1 minor criterion or >3 minor criteria B- or C-findings? Major criterion Multifocal dense infiltrates of MCs, 15 MCs in aggregates in BM biopsies Minor criteria (modified) 25% of all MCs are atypical cells (type I or type II) on BM smears or are spindleshaped in MC infiltrates detected on sections of visceral organs KIT D816 mutation or other activating KIT mutation MCs exhibit CD25 (and/or CD2) Baseline serum tryptase level >20 µg/l B-findings BM MC infiltration >30% and serum tryptase >200µg/L Organomegaly BM with proliferation or dysplasia C-findings Cytopenia(s): Neutrophils <1x10 9 /μl, Hb<10 g/dl and/or platelets <100x10 9 /μl Hepatomegaly with impaired liver function and ascites Palpable splenomegaly + associated hypersplenism Malabsorption with hypoalbuminemia and significant weight loss Skeletal lesions: large-sized osteolyses with pathologic fractures Life-threatening organ damage in other organ systems that is caused by local MC infiltration
10 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS ISM 0 or 1 B-finding, No C-finding SSM At least 2 of 3 B- findings SM-AHN 4 Suspected systemic mastocytosis (SM) BONE MARROW (BM) BIOPSY Aspirate, histology, immunohistochemistry, cytogenetics, FACS analysis Quantification of mast cell (MC) infiltration Presence and quantification of KIT D816V 2 Mast cell leukemia (MCL)? 3 Associated hematologic neoplasm (AHN)? Multilineage involvement? CD34+ blasts? Diagnosis of SM (according to WHO 2016): 1 major + 1 minor criterion or >3 minor criteria B- or C-findings? ASM C-findings 1,2 An elevated serum tryptase (normal value <11.4µg/L) AND presence of a KIT D816 mutation (KIT D816V in >90% of cases) make diagnosis of SM very likely. 3 MCL is defined by >20% mast cells in BM cytology (not histology!). 4 In the majority of SM-AHN cases, the AHN is also KIT D816V positive and treatment is according to SM. In few cases, SM and AHN may represent two independent diseases and treatment of SM and AHN may differ. MC: Mast Cell, ISM: Indolent Systemic Mastocytosis, SM-AHN: Systemic Mastocytosis with associated hematologic neoplasm, ASM: Aggressive Systemic Mastocytosis, MCL: Mast Cell Leukemia, BM: Bone Marrow, SSM: Smoldering Systemic Mastocytosis MCL Major criterion Multifocal dense infiltrates of MCs, 15 MCs in aggregates in BM biopsies Minor criteria (modified) 25% of all MCs are atypical cells (type I or type II) on BM smears or are spindleshaped in MC infiltrates detected on sections of visceral organs KIT D816 mutation or other activating KIT mutation MCs exhibit CD25 (and/or CD2) Baseline serum tryptase level >20 µg/l B-findings BM MC infiltration >30% and serum tryptase >200µg/L Organomegaly BM with proliferation or dysplasia C-findings Cytopenia(s): Neutrophils <1x10 9 /μl, Hb<10 g/dl and/or platelets <100x10 9 /μl Hepatomegaly with impaired liver function and ascites Palpable splenomegaly + associated hypersplenism Malabsorption with hypoalbuminemia and significant weight loss Skeletal lesions: large-sized osteolyses with pathologic fractures Life-threatening organ damage in other organ systems that is caused by local MC infiltration
11 SM subtypes and clinical course SM-AHN ASM ± AHN Indolent SM MCL ± AHN (A)SM-/MCLsAML Advanced SM SM-AHN: ASM: MCL: (A)SM/MCL-sAML: Systemic Mastocytosis with Associated Hematologic Neoplasm dysplastic and/or myeloproliferative features MDS, MDS/MPN, MPN Aggressive Systemic Mastocytosis Hb <10 g/dl, platelets <100 g/l, albumin <25 g/l, splenomegaly, ascites, malabsorption, weight loss >10% (C-findings) Mast Cell Leukemia >20% mast cells in bone marrow smear with associated secondary Acute Myeloid Leukemia >30% blasts
12 Survival Survival with SM ISM: indolent SM ASM: aggressive SM MCL: mast cell leukemia AHD: associated hematologic (non-mast cell lineage) disorder Lim KH et al. SM in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113:
13 CLINICAL FINDINGS Symptoms: flushing, anaphylaxis, diarrhea, fatigue, bone pain, pruritus, constitutional symptoms Skin lesions (urticaria pigmentosa) Splenomegaly, hepatomegaly, ascites Abdominal lymphadenopathy Osteoporosis/osteolyses LAB ABNORMALITIES Serum tryptase 1 Cytopenia(s) Monocytosis, eosinophilia Albumin Alkaline phosphatase Vitamin B12 MOLECULAR ABERRATIONS KIT D816 mutation in peripheral blood 2 Additional myeloid mutations, e.g. SRSF2, ASXL1, RUNX1, JAK2 V617F, EZH2, RAS ISM 0 or 1 B-finding, No C-finding SSM At least 2 of 3 B- findings H1-/H2-antagonists MC stabilizers Leukotriene antagonists Steroids (topic and/or systemic) Interferon-alpha (inadequately controlled symptoms, off-label) SM-AHN 4 Suspected systemic mastocytosis (SM) BONE MARROW (BM) BIOPSY Aspirate, histology, immunohistochemistry, cytogenetics, FACS analysis Quantification of mast cell (MC) infiltration Presence and quantification of KIT D816V 2 Mast cell leukemia (MCL)? 3 Associated hematologic neoplasm (AHN)? Multilineage involvement? CD34+ blasts? Diagnosis of SM (according to WHO 2016): 1 major + 1 minor criterion or >3 minor criteria B- or C-findings? ASM C-findings MCL Midostaurin (SM-AHN, ASM, MCL) Imatinib (for sensitive KIT mutations only, <1%) Cladribine (off-label) Interferon-alpha (off-label) Hydroxyurea (for the AHN component) 1,2 An elevated serum tryptase (normal value <11.4µg/L) AND presence of a KIT Allogeneic stem cell transplantation (in eligible D816 mutation (KIT D816V in >90% of cases) patients in best achievable remission) make diagnosis of SM very likely. 3 MCL is defined by >20% mast cells in BM cytology (not histology!). Major criterion Multifocal dense infiltrates of MCs, 15 MCs in aggregates in BM biopsies Minor criteria (modified) 25% of all MCs are atypical cells (type I or type II) on BM smears or are spindleshaped in MC infiltrates detected on sections of visceral organs KIT D816 mutation or other activating KIT mutation MCs exhibit CD25 (and/or CD2) Baseline serum tryptase level >20 µg/l B-findings BM MC infiltration >30% and serum tryptase >200µg/L Organomegaly BM with proliferation or dysplasia C-findings Cytopenia(s): Neutrophils <1x10 9 /μl, Hb<10 g/dl and/or platelets <100x10 9 /μl Hepatomegaly with impaired liver function and ascites Palpable splenomegaly + associated hypersplenism Malabsorption with hypoalbuminemia and significant weight loss Skeletal lesions: large-sized osteolyses with pathologic fractures Life-threatening organ damage in other organ systems that is caused by local MC infiltration 4 In the majority of SM-AHN cases, the AHN is also KIT D816V positive and treatment is according to SM. In few cases, SM and AHN may represent two independent diseases and treatment of SM and AHN may differ. MC: Mast Cell, ISM: Indolent Systemic Mastocytosis, SM-AHN: Systemic Mastocytosis with associated hematologic neoplasm, ASM: Aggressive Systemic Mastocytosis, MCL: Mast Cell Leukemia, BM: Bone Marrow, SSM: Smoldering Systemic Mastocytosis
14 Best Value, Change in Bone Marrow Mast Cell Infiltration From Baseline (%) Best Value, Change in Tryptase Level From Baseline (%) Changes in Bone Marrow Mast Cell Burden and Serum Tryptase Level 100 Decrease 50% confirmed during 2 consecutive bone marrow biopsies: * 100 Decrease 50% confirmed during 2 cycles (56 days): 50 No (n=48) Yes (n=24) 50 No (n=57) Yes (n=32) *Best value: 160% increase in bone marrow mast cells versus baseline. Best value: 118% and 185% increase in serum tryptase level versus baseline. Gotlib J et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEJM 2016; 374;
15 Best change in spleen volume from baseline Best Value, Change in Spleen Volume From Baseline (%) 40 Responders (n=30) Nonresponders (n=9) /39 decreased volume 35% /39 increased volume -35% /39 decreased volume Gotlib J et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEJM 2016; 374;
16 Patients (%) Response over time Major Response Partial Response Stable Disease Progresive Disease Not Evaluable n = Months Major response: 1C-finding resolved, - incomplete: MC and/or tryptase >50% and/or organomegaly >50%; - pure clinical: tryptase 50%-0% Good partial response: 1 C-finding resolved by >50% Gotlib J et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEJM 2016; 374;
17 Forrest plot for subgroup analysis of response Category Response (95% CI), % Overall (n=89) 60 (49-70) ASM (n=16) 75 (48-93) SM-AHN (n=57) 58 (44-71) MCL (n=16) 50 (25-75) MCL (n=16) 50 (25-75) Non-MCL (n=73)* 62 (50-73) With AHN (n=63) 57 (44-70) Without AHN (n=26) 73 (45-92) KIT D816V+ (n=73) 63 (51-74) KIT D816V /unknown (n=16) 44 (20-70) Prior therapies (n=37) 62 (45-78) No prior therapies (n=52) 58 (43-71) AHN: Associated Hematologic Neoplasm, ASM: Aggressive Systemic Mastocytosis, SM-AHN: Systemic Mastocytosis with associated hematologic neoplasm, MCL: Mast Cell Leukemia; Non-MCL: Non-Mast Cell Leukemia Patients (%) Gotlib J et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEJM 2016; 374;
18 MSAS Symptom Burden Hair loss Mouth sores Difficulty swallowing Constipation Vomiting Lack of energy Feeling drowsy 100 Difficulty sleeping Pain Weight loss Feeling bloated Don t look like myself Urinary problems Numbness in hands/feet Problems with sex Difficulty concentrating Dry mouth Worrying Feeling nervous Skin changes Change in way food tastes Shortness of breath Cough Feeling sad Dizziness Swelling of arms/legs Itching Nausea MSAS: Memorial Symptom Assessment Scale, TMSAS: Total Memorial Symptom Assessment Scale Subscore Diarrhea Sweats Feeling irritable Lack of appetite Baseline TMSAS Best TMSAS value on treatment Gotlib J et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEJM 2016; 374;
19 Patients Surviving (%) Overall survival according to subgroups Kaplan-Meier Estimates (95% CI), % 100 SM Subgroup Median OS (95% CI), months 1-Year OS 2-Year OS 3-Year OS ASM (n=16) NR (28.7-NE) 93 (61-99) 86 (55-96) 65 (18-90) SM-AHN (n=57) 20.7 ( ) 72 (58-82) 49 (34-63) 44 (27-59) MCL (n=16) 9.4 (7.5-NE) 47 (22-69) 26 (6-54) 26 (6-54) Months ASM: Aggressive Systemic Mastocytosis, SM: Systemic Mastocytosis, SM-AHN: Systemic Mastocytosis with associated hematologic neoplasm, MCL: Mast Cell Leukemia; OS: Overall survival Gotlib J et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEJM 2016; 374;
20 Univariate and multivariate analyses of on-treatment variables regarding overall survival b c d e f KIT D816V in peripheral blood AP reduction 50% or normalization Cheson criteria for transfusions response criteria according to Valent response criteria according to IWG-MRT & ECNM consensus criteria MC: Mast Cell, BM: Bone Marrow, AP: Alkaline Phosphatase, Hb: Hemoglobin, PLT: Platelet Count, IWG-MRT: International Working Group-Myeloproliferative Neoplasms Research and Treatment, EAB: Expressed Allel Burden Jawhar M et al. Response and Progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers Blood 2017; 130(2):
21 Patients Included in Analyses Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788.
22 Comparable Baseline Characteristics, Except Age Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. SM: Systemic Mastocytosis
23 Overall Survival Comparisons Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. SM: Systemic Mastocytosis
24 Overall Survival Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. OS: Overall Survival, HR: Hazard Ratio, CI: Confidence Interval.
25 Overall Survival From Data of Diagnosis Based on Matched Pairs Using the Propensity Score a Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. OS: Overall Survival, HR: Hazard Ratio, CI: Confidence Interval.
26 Subgroup Analysis of Overall Survival Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. SM: Systemic Mastocytosis, AHN: Associated Hematologic Neoplasm, MCL: Mast Cell Leukemia
27 Multivariate Analysis of Overall Survival Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. ASM: Aggressive Systemic Mastocytosis, MCL: Mast Cell Leukemia, AHN: Associated Hematologic Neoplasm.
28 Overall Survival From Date of Last Treatment Received for Advanced SM Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. OS: Overall Survival, HR: Hazard Ratio, CI: Confidence Interval.
29 Conclusions Reiter A et al. Pooled Analysis of Midostaurin Clinical Study Data in Patients with advsm compared with historic controls. EHA 2017; Abstract S788. SM: Systemic Mastocytosis
30 Midostaurin in advanced SM Overall response rate: 60% Improvement of: Symptoms (30/32 MSAS, splenomegaly 70%) Serum tryptase KIT-allele burden Bone marrow mast cell infiltration C-findings (organ dysfunction) BUT: no complete remission Lower risk of death than historical controls Adverse events: Nausea Vomiting SM: Systemic Mastocytosis, MSAS: Memorial Symptom Assessment Scale
Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationAvapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM)
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using
More informationSystemic Mastocytosis: Seldomly Seen, Multiple Manifestations
Systemic Mastocytosis: Seldomly Seen, Multiple Manifestations Ryan Cassaday, MD HematologyFellows Conference June 3, 2011 Outline Why this topic, and case discussion Brief background Classification i of
More informationMayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
REGULAR ARTICLE Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models Animesh Pardanani, 1 Sahrish Shah, 1 Francesco Mannelli, 2 Yoseph C. Elala, 1 Paola Guglielmelli,
More information9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology
Disclosure MAST CELLNEOPLASM I have nothing to disclose. Young S. Kim MD Dept. of Pathology 1 Objectives What is mast cell lineage? Changes in updated WHO 2016 mastocytosis Issues of Mastocytosis CD30
More informationDiagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.
Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More information2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228
2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07
More informationMast Cell Disease. Daniel A. Arber, MD Stanford University, Stanford CA
Mast Cell Disease Daniel A. Arber, MD Stanford University, Stanford CA Mast cell disease, or mastocytosis, includes a variety of disorders that are characterized by the presence of mast cell aggregates
More informationPresenter Disclosure Information
Welcome to Master Class for Oncologists Session 3: 2: PM 3:3 PM Pasadena, CA May 1, 21 Myeloproliferative Neoplasms 21 Speaker: Ayalew Tefferi Mayo Clinic, Rochester, MN Presenter Disclosure Information
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationSystemic mastocytosis: overview and new insights in prognosis and therapy
3 Systemic mastocytosis: overview and new insights in prognosis and therapy G. Deslypere, MD 1, T. Devos, MD, PhD 2, M. Delforge, MD, PhD 2, G. Verhoef, MD, PhD 2 Systemic mastocytosis is an orphan myeloproliferative
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationJuvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationSystemic mastocytosis:
Systemic mastocytosis: Flow cytometry and Molecular Biology Katrien Vermeulen 21 oktober 2016 Cuteanous mastocytosis Major criterion Typical skin lesions of mastocytosis associated with Darier s sign Minor
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationSynonyms. Mast cell disease Mast cell proliferative disease
Mastocytosis Definition Mastocytosis is a proliferation of mast cells and their subsequent accumulation in one or more organ systems. Mast cells are derived from hematopoietic progenitors, thus mastocytosis
More informationMastocytosis. Dr Sarah Sasson SydPath Registrar 24 th November 2014
Mastocytosis Dr Sarah Sasson SydPath Registrar 24 th November 2014 Introduction to Mastocytosis A rare myeloid malignancy resulting from a clonal, neoplastic proliferation of morphologically and immunotypically
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationChronic Myelomonocytic Leukemia with molecular abnormalities SH
Chronic Myelomonocytic Leukemia with molecular abnormalities SH2017-0351 Madhu P. Menon MD,PhD, Juan Gomez MD, Kedar V. Inamdar MD,PhD and Kristin Karner MD Madhu P Menon, MD, PhD Henry Ford Hospital Patient
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationA GUIDE TO TREATMENT WHILE TAKING RYDAPT FOR ADVANCED SM
For patients with 3 types of systemic mastocytosis (SM)* * Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL) are
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationCase Report. Introduction. Mastocytosis associated with CML Hematopathology - March K. David Li 1,*, Xinjie Xu 1, and Anna P.
Mastocytosis associated with CML Hematopathology - March 2016 Case Report Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) involving chronic myelogenous
More informationCME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1.
Hematopathology / New Mastocytosis Flow Cytometry Approach High-Sensitivity Flow Cytometric Analysis for the Evaluation of Systemic Mastocytosis Including the Identification of a New Flow Cytometric Criterion
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationChronic myelomonocytic leukemia. Lymphoma Tumor Board. May 26, 2017
Chronic myelomonocytic leukemia Lymphoma Tumor Board May 26, 2017 Myeloproliferative Neoplasms CMML has an estimated incidence of less than 1 per 100,000 persons per year Myeloproliferative neoplasms (MPN)
More informationSupervisor: Prof. Dr. P Vandenberghe Dr. C Brusselmans
Contribution of molecular diagnosis in eosinophilia/hypereosinophilia Eosinophilia Hypereosinophilia Hypereosinophilic syndrome Immune mediated hypereosinophilia Chronic eosinophilic leukemia (NOS)/ Idiopathic
More informationMast cell leukemia with prolonged survival on PKC412/midostaurin
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Mast cell leukemia with prolonged survival on PKC412/midostaurin Xiangdong Xu Friederike H. Kreisel John L.
More informationCASE 106. Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation
CASE 106 Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation Gabriel C. Caponetti, MD University of Pennsylvania, US Clinical history 69, F peripheral neuropathy, refractory
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationBench to Bedside: Advances in Mastocytosis Tryptase PD-L1
Bench to Bedside: Advances in Mastocytosis Tryptase PD-L1 Tracy I. George, M.D. Associate Professor of Pathology University of New Mexico Health Sciences Center 1 Disclosures Allakos grant Blueprint Medicine
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationStifel Nicolaus 2013 Healthcare Conference. John Scarlett, M.D. Chief Executive Officer September 11, 2013
Stifel Nicolaus 2013 Healthcare Conference John Scarlett, M.D. Chief Executive Officer September 11, 2013 1 forward-looking statements Except for the historical information contained herein, this presentation
More informationMastocytosis An Unusual Clonal Disorder of Bone Marrow Derived Hematopoietic Progenitor Cells
Mastocytosis An Unusual Clonal Disorder of Bone Marrow Derived Hematopoietic Progenitor Cells Hans-Peter Horny, MD Key Words: Mastocytosis; Mast cell; Bone marrow; KITD816V; Systemic mastocytosis with
More informationICCS e-newsletter CSI Case Laura Sánchez-Muñoz, Jose Mario T. Morgado, Cristina Teodosio
ICCS e-newsletter CSI Case Laura Sánchez-Muñoz, Jose Mario T. Morgado, Cristina Teodosio Instituto de Estudios de Mastocitosis and Centro de Investigación del Cáncer Spanish Network on Mastocytosis Spain
More informationLondon Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12
London Cancer Myelofibrosis guidelines August 2013 Review August 2013 Version v1.0 Page 1 of 12 CONTENTS 1. DIAGNOSIS... 3 1a. BCSH (2012)... 3 1b. WHO (2009) diagnostic criteria for PMF:... 4 2. MOLECULAR
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationDisclosures for Angela Fleischman
Disclosures for Angela Fleischman Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Sierra, Incyte None None None Incyte None Presentation includes
More informationGLEEVEC (imatinib mesylate) Capsules FACT SHEET
Health Canada Santé Canada GLEEVEC (imatinib mesylate) Capsules FACT SHEET CONDITIONAL APPROVAL OF GLEEVEC This fact sheet notifies the Canadian public that Health Canada has issued a conditional marketing
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationUpdate on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester
Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms Kaaren Reichard Mayo Clinic Rochester Reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Present
More informationCase Presentation. Attilio Orazi, MD
Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia
More informationMast Cell Activation Syndrome
Mast Cell Activation Syndrome Clinical Questionnaire Description Today s Date: Patient Name: Please indicate yes or no for the following symptoms and traits: (If you are not familiar with a particular
More informationHypereosinophili c syndrome
Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary
More informationShould Intermediate-I risk PMF be transplanted immediately or later? Position: Later
Should Intermediate-I risk PMF be transplanted immediately or later? Position: Later Vikas Gupta, MD, FRCP, FRCPath Associate Professor Department of Medicine Leukemia/BMT Programs Princess Margaret Cancer
More informationPathogenesis and management of CMML
Pathogenesis and management of CMML Raphaël Itzykson, Hôpital Saint-Louis, Paris International Conference of the Korean Society of Hematology March 29th 2018 대한혈액학회 Korean Society of Hematology COI disclosure
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationIntro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia
Settima Giornata Fiorentina dedicata ai pazienti con malattie mieloproliferative croniche Sabato 13 Maggio 2017 CRIMM Centro di Ricerca e Innovazione per le Malattie Mieloproliferative AOU Careggi Intro
More informationMYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
More informationNew Therapies for MPNs
Pomalidomide and IMIDS in Myelofibrosis New Therapies for MPNs Fourth International Workshop on CML and MPN Natchez Louisiana Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Director
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationMYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationPractical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology
Practical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology Angela Fleischman MD PhD UC Irvine March 9, 2019 Disclosures: Angela Fleischman
More informationJeanne Palmer, MD Mayo Clinic, Arizona
Setting the stage for Transplant in MPN Jeanne Palmer, MD Mayo Clinic, Arizona What will be covered What is a bone marrow transplant? When to start thinking about bone marrow transplant Timing of transplant
More informationEosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation
Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation American Society for Clinical Pathology 2014 Annual Meeting Presented by: Matthew T. Howard, MD Assistant
More informationMDS/MPN: What it is and How it Should be Treated?
MDS/MPN: What it is and How it Should be Treated? MDS MPN Rachel Salit, MD Assistant Member Fred Hutchinson Cancer Research Center rsalit@fredhutch.org MDS Founda>on Pa>ent & Family Forum: May 20, 2017
More informationAbstracting Hematopoietic Neoplasms
CASE 1: LYMPHOMA PHYSICAL EXAMINATION 43yo male with a history of lower gastrointestinal bleeding and melena undergoing colonoscopy and biopsy to rule out neoplasm versus inflammation. Patient had no other
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationMyeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination
Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination Arati V. Rao, M.D. Division of Medical Oncology and Geriatrics Duke University Medical Center Durham
More informationTisch Cancer Institute, Icahn School of Medicine at Mount Sinai; MPN-RC (US), 2 H Lee Moffitt Cancer Center (US), 3
Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationPost-ASH 2015 CML - MPN
Post-ASH 2015 CML - MPN Fleur Samantha Benghiat, MD, PhD Hôpital Erasme, Brussels 09.01.2016 1. CML CML 1st line ttt Prognosis Imatinib Nilotinib Response Discontinuation Dasatinib Low RISK PROFILE High
More informationWhen Cancer Looks Like Something Else: How Does Mutational Profiling Inform the Diagnosis of Myelodysplasia?
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationDe novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child
Zheng et al. Diagnostic Pathology (2018) 13:14 https://doi.org/10.1186/s13000-018-0691-2 CASE REPORT Open Access De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationJAKAFI (ruxolitinib phosphate) oral tablet
JAKAFI (ruxolitinib phosphate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationImmunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis
O R I G I N A L A R T I C L E Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis P.L.A. van Daele 1,2*, B.S. Beukenkamp 2, W.M.C. Geertsma-Kleinekoort 3,
More informationEfficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
The new england journal of medicine Original Article Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis Jason Gotlib, M.D., Hanneke C. Kluin Nelemans, M.D., Ph.D., Tracy I. George, M.D.,
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationAll Wales Lymphoma Panel Lymphoma Course April 2015 Wales Millennium Centre Cardiff
All Wales Lymphoma Panel Lymphoma Course 23-24 April 2015 Wales Millennium Centre Cardiff Case Histories Online slides at: http://dental.uwcm.ac.uk:82/awlp%20course%202015/view.apml? Professor Sebastian
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationBy Angela Gascoigne Haematology CNS Chesterfield Royal Hospital
By Angela Gascoigne Haematology CNS Chesterfield Royal Hospital Myeloproliferative Neoplasms Essential Thrombocythaemia Polycythaemia Vera Myelofibrosis Essential Thrombocythaemia (ET) Chronic condition
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationHow I Treat Myelofibrosis. Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom
How I Treat Myelofibrosis Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom Primary Myelofibrosis Archiv Fur Pathol. 1879;78:475-96. 2 cases of leukemia with peculiar blood and marrow findings
More informationMyelodysplastic syndromes
Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.
More informationA Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Lewis R. Silverman, MD 1, Katherine Hearn, RN 2, Rosalie
More informationSponsor / Company: Sanofi Drug substance(s): SAR302503
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More information